Related Experiment Video
Updated: Jan 19, 2026
Intravenous Administration of Therapeutic Nanoparticles in a Murine Glioblastoma Model
Published on: August 29, 2025
Methylxanthines: Potential Therapeutic Agents for Glioblastoma
Daniel Pérez-Pérez1,2, Iannel Reyes-Vidal2, Elda Georgina Chávez-Cortez2
1PECEM, Faculty of Medicine, National Autonomous University of México, México City 04510, Mexico.
Abstract:
Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Currently, treatment is ineffective and the median overall survival is 20.9 months. The poor prognosis of GBM is a consequence of several altered signaling pathways that favor the proliferation and survival of neoplastic cells. One of these pathways is the deregulation of phosphodiesterases (PDEs). These enzymes participate in the development of GBM and may have value as therapeutic targets to treat GBM. Methylxanthines (MXTs) such as caffeine, theophylline, and theobromine are PDE inhibitors and constitute a promising therapeutic anti-cancer agent against GBM. MTXs also regulate various cell processes such as proliferation, migration, cell death, and differentiation; these processes are related to cancer progression, making MXTs potential therapeutic agents in GBM.
Insights
Methylxanthines (MXTs) show promise as a novel anti-cancer therapy for glioblastoma (GBM), a highly aggressive brain tumor. By inhibiting phosphodiesterases (PDEs), MXTs may offer a new treatment avenue to improve patient survival rates.
Area of Science:
- Neuro-oncology
- Molecular biology
- Pharmacology
Background:
- Glioblastoma (GBM) is an aggressive primary brain tumor with poor prognosis and ineffective treatments.
- Altered signaling pathways, including phosphodiesterase (PDE) deregulation, contribute to GBM proliferation and survival.
- PDEs are implicated in GBM development and represent potential therapeutic targets.
Purpose of the Study:
- To explore the therapeutic potential of methylxanthines (MXTs) as anti-cancer agents against glioblastoma.
- To investigate the role of MXTs in regulating cell processes relevant to GBM progression.
Main Methods:
- The study focuses on the mechanism of action of methylxanthines (MXTs) as phosphodiesterase (PDE) inhibitors.
- Analysis of how MXTs affect key cellular processes involved in cancer progression.
Main Results:
- Methylxanthines (MXTs), including caffeine, theophylline, and theobromine, are identified as PDE inhibitors.
- MXTs demonstrate potential as anti-cancer agents against GBM by targeting deregulated pathways.
- MXTs regulate critical cell processes such as proliferation, migration, and cell death, which are relevant to GBM.
Conclusions:
- Methylxanthines (MXTs) represent a promising therapeutic strategy for glioblastoma (GBM) due to their PDE inhibitory activity.
- Targeting PDEs with MXTs could offer a novel approach to combat GBM progression and improve patient outcomes.
Related Concept Videos
02:29Intravenous Administration of Therapeutic Nanoparticles in a Murine Glioblastoma Model
09:57Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model
09:18TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents
01:24Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
02:24Microinjection-Based Delivery of a Therapeutic Agent into an Awake Rodent Brain
09:02Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model